Cranbury pharma firm files for IPO worth up to $100M

PMV Pharmaceuticals Inc., a Cranbury-based company working on a cancer treatment, has filed for an initial public offering that could be worth up to $100 million, according to a filing with the Securities and Exchange Commission.

The company said in the filing that it hopes to issue common stock worth up to that amount, under the ticker symbol PMVP.

Underwriters include Goldman Sachs & Co. LLC, BofA Securities, Cowen and Evercore ISI, according to the filing prospectus.